POLE S	
DEC 15 2003	FEICE
Etale Land	9

Sheet

RADE Babstitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

	Complete if Known
Application Number	09/308,080
Filing Date	October 28, 1999
First Named Inventor	Gonzales, Ph.D., Frank
Art Unit	1652
Examiner Name	Ramirez, Delia M.
Attorney Docket Number	015280-271100US

	U.S. PATENT DOCUMENTS+						
′		Document Number			Ones California Linea Milhorn		
Examiner Initials*	Cite No.1	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
				1.			
				-	9		
		 					

				FOREIGN PA	TENT DOCUME	NTS		
		Foreign Patent Document			Name of Patentee or	Pages, Columns, Lines, Where Relevant		
Examiner Initials*	Cite No.1		Applicant of Cited Document	Passages or Relevant Figures Appear	т•			
2012	1	wo	95/28489		10-26-1995	The UAB Research Foundation		
<u> </u>					_			
								\Box
				1				
		····						
	ļ							
		1						

Examiner Signature	Date Considered	3	181	04	· · · · · · · · · · · · · · · · · · ·

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. *Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *S Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. *Applicant is to place a check mark here if English language Translation is attached. *60097522 v1**

PTO/SB/08B (08-03) Substitute for form 1449B/PTO Complete if Known Application Number 09/308,080 MFORMATION DISCLOSURE October 28, 1999 Filing Date STATEMENT BY APPLICANT Gonzales, Ph.D., Frank First Named Inventor 1652 Art Unit (use as many sheets as necessary) Ramirez, Delia M. Examiner Name 015280-271100US 2 Attorney Docket Number Sheet of

		NON PATENT LITERATURE DOCUMENTS							
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							
m	2	KUILENBURG, Andre B.P. et al.: "Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD Deficiency"; Clinical Cancer Research, Vol. 7; pp. 1149-1153; May 2001							
on	3	KUIVANIEMI, Helena et al.: "Identical G+1 to A mutations in three different introns of the Type III procollagene gene (COL3A1) produce different patterns of RNA splicing in three variants ot Ehlers-Danlos Syndrome IV"; J. Biological Chemistry, Vol. 265, No. 20; pp. 12067-12074; July 15, 1990	_						
M	4	YOKOTA, Hiroshi et al.: "cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, and enzyme associated with 5-flouorouracli toxicity and congenital thymine uracilura"; J. Biological Chemistry, Vol. 269, No. 37; pp. 23192-23196; September 16, 1994							
on	5	OMIM Entry for "Dyhydropyrimidine Dehydrogenase; DPYD" printed on December 3, 2003; http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=274270; 10 pages							
•									
		·							

Examiner Signature	P	Date Considered	3/18/04

'EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

ORIGINALLY FILED

Please	type a	olus	sian	(+) inside	this	box	→	+
r icase	IVUE a	DIUS	217111	ľ	11113100		~~		

PTO/SB/08B (08-00)

. ...

Approved for use through 10/31/2002 OMB 0851-0031 Under the Paperwork Reduction Act of 1995, no perso Com of beaution id to a collection of information unless it contains a valid QMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Compl te If Known **Application Number** 09/308,080 Filing Date October 28, 1999 Frank Gonzale First Named Inventor **Group Art Unit**

(use as many sheets as necessary)

of

Sheet

Examiner Name Steadman, D Attorney Docket Number 015280-271100US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Cite item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue Examiner number(s), publisher, city and/or country where published. No. Initials Gonzalez, F., et al., "Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine AC déhydrogenase deficiency." TIPS, 16:325-327 (1995). Y, et al. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme ΑĎ associated with 5-flourouracil toxicity and congenital thyrnine uraciluria, J. Blol. Chem., 269:23192-23196 (1994). JOURNAL BIOLOGICAL CHEMISTRY, vol. 264, no. 20, July 1990, pages 12067-74, XP002032866 ΑE KUIVANIEMI, H., ET AL: "Identical G to a mutations in three different introns of the type III procollagen gene (COL3A1) produce different patterns of RNA splicing in three variants of Ehlers-Danlos Syndrome IV." ee abstract Meinsma, R., et al., "Human Polymorphism in Drug Metabolism: Mutation in the Dihydropyrimidine Dehydrogenase Gene Resutls in Exon Skipping and Thymine Uracilurea," <u>DNA & Cell. Biol.</u>, 14(1)1-8 (1995). NUCLEIC ACIDS RESEARCH. vol. 15 no. 14, 1987, pages 5613-28, XP002032865 AG MARVIT, J. ET AL: "GT to AT transition at a splice donor site causes skipping of the preceeding exon in benviketonuria see abstract SINGAPORE JOURNAL OF OBSTETRICS AND GYNECOLOGY. vol. 26, no. 3, November 1995. pages 176-86, XP000600337 ROY ET AL: "molecular scanning of human diseases" see the whole document. Vreken, P., et al., "A point mutation in an Invariant splice donor site leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase deficiency," <u>J. Inherit. Metab. Dis.</u>, 19(5):845-54 (1996). Wei, X., et al. "Molecular Basis of the Human Dihydropyrimidine Dehydrogenase Deficiency and 5-Fluorouracil Toxicity," J. Clin. Invest., 98(3)610-815 (1998).

	· · · · · · · · · · · · · · · · · · ·	والتناف المساول والمساول	
Examiner	na	Date	chata
Signature	NOS	Considered	6/30/02

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231. WC 9039543 v1

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.